CD1 is an MHC class I-like antigen-presenting molecule consisting of a heavy chain and ␤2-microglobulin light chain. The in vitro refolding of synthetic MHC class I molecules has always required the presence of ligand. We report here the use of a folding method using an immobilized chaperone fragment, a protein disulphide isomerase, and a peptidyl-prolyl cis-trans isomerase (oxidative refolding chromatography) for the fast and efficient assembly of ligand-free and ligand-associated CD1a and CD1b, starting with material synthesized in Escherichia coli. The results suggest that ''empty'' MHC class I-like molecules can assemble and remain stable at physiological temperatures in the absence of ligand. The use of oxidative refolding chromatography thus is extended to encompass complex multisubunit proteins and specifically to members of the extensive, functionally diverse and important immunoglobulin supergene family of proteins, including those for which a ligand has yet to be identified.
CD1 is an MHC class I-like antigen-presenting molecule consisting of a heavy chain and ␤2-microglobulin light chain. The in vitro refolding of synthetic MHC class I molecules has always required the presence of ligand. We report here the use of a folding method using an immobilized chaperone fragment, a protein disulphide isomerase, and a peptidyl-prolyl cis-trans isomerase (oxidative refolding chromatography) for the fast and efficient assembly of ligand-free and ligand-associated CD1a and CD1b, starting with material synthesized in Escherichia coli. The results suggest that ''empty'' MHC class I-like molecules can assemble and remain stable at physiological temperatures in the absence of ligand. The use of oxidative refolding chromatography thus is extended to encompass complex multisubunit proteins and specifically to members of the extensive, functionally diverse and important immunoglobulin supergene family of proteins, including those for which a ligand has yet to be identified.
minichaperone ͉ protein folding ͉ GroEL ͉ DsbA ͉ PPI H uman CD1a, -b, -c, -d, and -e molecules are a family of MHC class I-like transmembrane glycoproteins that map to chromosome 1 and have restricted polymorphism (1) (2) (3) (4) . Although CD1d may exist as a ␤ 2 -microglobulin-(␤ 2 m) independent form (5), CD1 proteins are generally heterodimers of a CD1 heavy chain in noncovalent association with a ␤ 2 m light chain. CD1-mRNA molecules are spliced alternatively to generate cell surface, intracellular, and secretory isoforms (6) .
Unlike MHC class I molecules that bind peptides (7), CD1 molecules bind and present a diverse range of nonclassical hydrophobic lipid and glycolipid ligands that include lipoglycan, lipoarabinomannan, mycolic acid, phosphatidylinositolmannan, glucose monomycolate, ␣-glucosylceramide, hexosyl-1-phosphoisoprenoids, and mannosyl-␤1-phosphodolichols (8) (9) (10) (11) (12) (13) . They also present hydrophobic peptides (14, 15) . This specialization of function is reflected in the three-dimensional structure of mouse CD1d (the only published CD1 structure). The antigen-binding pocket is narrow, deep, hydrophobic, and lined by residues with minimal polymorphism (16) (8) (9) (10) (11) (12) . Although apparently ligand-free CD1 and MHC class I molecules have been synthesized in Drosophila melanogaster cells that lack the proteins necessary for intracellular peptide loading (17) , crystallographic studies of mouse CD1d made in this system demonstrate electron density in the ligand-binding groove, suggesting that they may not be ligand-free (16) .
Foldases and molecular chaperones are integral components of the in vivo cellular folding machinery (18) . For MHC class I (19) and CD1 (20) , calnexin and calreticulin provide chaperoning activity. The mechanism by which CD1 molecules are loaded with lipid antigen has not been elucidated fully, but because it is independent of the transporter associated with antigen processing (21) and occurs in endosomes or on the cell surface rather than in the endoplasmic reticulum, it is likely that CD1 employs a different pathway from that used by MHC class I (13, (22) (23) (24) .
The cell-free assembly of MHC class I heterodimers requires the presence of exogenous ligand to form a ternary complex with the MHC class I heavy chain and ␤ 2 m. Refolding in the presence of irrelevant ligands or the absence of ligands does not yield stable complexes (25) (26) (27) (28) . We found, similarly, that denatured CD1 heavy chains refold inefficiently in a cell-free environment containing ␤ 2 m but lacking ligand. Oxidative refolding chromatography using an aqueous suspension of an equimolar mixture of agarose-gel bead immobilized prokaryotic miniGroEL (a minichaperone containing the apical domain of GroEL), DsbA (a protein disulphide isomerase), and a peptidyl-prolyl cis-trans isomerase (PPI) proved efficient in restoring the native conformation of scorpion toxin, which is a single polypeptide consisting of 63 amino acids (29) . In this paper, we show that this artificial folding system allows refolding of CD1a and -b heterodimers.
GAGACATGTA AGGAT TCT T T and B2M[F] (5Ј-T T-TCATATGATCCAGCGTACTCCAAAG).
Recombinant CD1a and -b and ␤ 2 m chains were expressed in E. coli (DE3) BL21 LysS. BL21 cells were electroporated and colonies inoculated into 2ϫ TY growth medium (1.6% tryptone͞1% yeast extract͞0.5% NaCl, pH 7.4) containing 100 g⅐ml Ϫ1 ampicillin and incubated at 27°C. Expression was induced with 1.0 mM isopropyl-␤-D-thiogalactopyranoside and growth was continued for 3 h at 37°C. Cell pellets were lysed in a French pressure cell and centrifuged at 10,000 ϫ g for 10 min. Inclusion bodies were washed several times in 10 mM Tris͞0.1 mM EDTA (pH 8.0) (40 ml) containing PMSF (50 g⅐ml
Ϫ1
), washed once in 1.0 M urea, flash frozen, and stored at Ϫ70°C. Protein was quantified by using Bio-Rad kits.
Refolding Procedure. Batchwise refolding was performed with an equimolar suspension of miniGroEL agarose, DsbA agarose, and PPI agarose (29) . Inclusion bodies were solubilized in freshly prepared 6 M GuHCl [containing 100 mM potassium phosphate buffer (pH 8.0)] and reduced with 0.1 M DTT.
The extent of unfolding and reduction was assessed by circular dichroism (CD) spectroscopy, measurement of turbidity, and quantification of free-SH groups by using 5,5Ј-dithiobis (2-nitrobenzoic acid). The refolding matrix was equilibrated with refolding buffer [100 mM potassium phosphate͞0.3 M Larginine HCl͞8 mM oxidized glutathione͞1.0 mM EDTA͞0.1 M PMSF (pH 8.0)]. Freshly denatured͞reduced CD1 heavy (-a or -b chains) and ␤ 2 m light chains were mixed together in varying molar ratios (1:1 to 1:10) immediately before refolding. A molar ratio of 1:3 (heavy͞light) was optimal. The mixture of heavy and light chains was added slowly, mixed, and diluted (1:100) into an aqueous suspension of the ternary refolding matrix. This mixture was rotated at 4°C for a range of incubation times (6 min to 12 h) and centrifuged at Ͻ1,000 ϫ g for 5 min. The soluble fraction was concentrated by using dialysis membranes covered with Dtrehalose (Sigma) and Ultrafree-15 centrifugal filter devices (Millipore). In conditions with ligand (ϩL), the glycolipid sulfatide (ceramide galactoside 3-sulfate, a newly established ligand of CD1a; A.S. and G.D., unpublished data) for CD1a and monosialoganglioside for CD1b were solubilized in PBS and sonicated (31) . Ligand was added to the refolding buffer-ternary matrix suspension immediately before refolding in a 10-fold (final) molar excess giving a final molar ratio of 1:3:10 (heavy chain͞␤ 2 m͞synthetic peptide). In ϪL conditions, no ligand was added.
Analysis of Refolded Protein. Gel filtration reverse-phase HPLC was performed on a Superdex-75 (Amersham Pharmacia) column equilibrated with 50 mM potassium phosphate buffer͞150 mM KCl͞2% (vol͞vol) glycerol (29) . Light-scattering analysis was done at 350 nm with a Hitachi 4000 spectrofluorometer (29) . Immunogenicity was tested in an inhibition immunoassay (6) by using the high-CD1a-expressing mutant NH17 (32) or the highCD1b-expressing mutant ER1 (3) as targets. Tissue-culture supernatant containing soluble CD1a was used as a positive control (6) . Monoclonal antibodies (mAbs) NA1͞34, 19H39, B17, and 10D12 were used as inhibitors. In the case of CD1b, mAb NU-T2 was used in the inhibition step. Rabbit anti-mouse HRP conjugate was used for detection. C͞D spectra were obtained by using a Jasco (Easton, MD) Model J-720 spectrometer. Calibration was performed by using (1S)-(ϩ)-10-camphorsulfonic acid (Aldrich) with a molar-extinction coefficient of 34.5 M Ϫ1 ⅐cm
at 285 nm and dichroism of 2.36 M Ϫ1 ⅐cm Ϫ1 at 290.5 nm. Samples from various refolding conditions (1.0 ml each) were analyzed by using refolding buffer as a blank. Spectra were recorded with protein concentrations of 0.15-0.30 mg⅐ml Ϫ1 in 25 mM potassium phosphate buffer (pH 8.0) and 0.1-cm quartz cuvettes at room temperature.
NH2-Terminal Sequencing and Stoichiometry. HPLC-purified CD1a and -b (ϩL and ϪL) was run on an SDS͞PAGE gel and electroblotted with a Bio-Rad Trans-Blot system. After Ponceau-S staining, bands corresponding to CD1a and -b heavy and ␤ 2 m light chains were excised. NH 2 -terminal sequence analysis was done on a Procise-494 protein sequencer (Applied Biosystems). Stoichiometry of the chains was determined by amino acid composition analysis of HPLC-purified bands. Norleucine was added to a solution of the bands and the mixture was concentrated in a centrifugal evaporator. Hydrolyzed material (gas phase HCl at 115°C for 22 h) was analyzed on an AmershamPharmacia Alpha Plus Series II.
Ultracentrifugation. Protein samples were dialyzed against 50 mM Tris (pH 8.0)͞60 mM GuHCl 2% glycerol͞1.0 mM EDTA. Sedimentation equilibrium experiments were conducted in a Beckman Optima XLI analytical ultracentrifuge (An60Ti rotor, 4°C) and spun at 10,000 or 9,000 rpm. Runs were overspeeded at 27,000 rpm for 6 h (33, 34). Absorbance at 275 nm was measured until equilibrium was reached. The specific densities of ␤ 2 m and CD1a were calculated as 0.7208 and 0.7212 ml⅐g Ϫ1 , respectively (density ϭ 1.009 g⅐ml Ϫ1 ) and corrected to 5°C by using SEDNTERP (34) . Mass-average apparent molecular weights were calculated as described (35) . Data were analyzed by direct fitting using ULTRASPIN software (http:͞͞www.mrc-cpe.cam. ac.uk͞ultraspin).
Results

Folding of CD1a and -b With and Without Ligand.
Overproduction of CD1a and -b heavy chains and ␤ 2 m light chains at high levels (30-40 mg⅐liter Ϫ1 ) as insoluble aggregates in the cytoplasm of E. coli was detected on SDS͞PAGE gels. Refolding was carried out in the presence (ϩL) and absence (ϪL) of synthetic ligand (sulfatide in the case of CD1a and monosialoganglioside for CD1b). If mixtures of denatured͞reduced synthetic chains of CD1a or -b (ϩL or ϪL) and ␤ 2 m were refolded in the presence of minichaperone or foldases only (DsbA agarose or PPI agarose), the ␤ 2 m remained in solution, whereas the CD1a or -b heavy chains formed a dense precipitate. In the presence of all three refolding components (ϩL and ϪL), the heavy chains were solubilized and there was no visible precipitate ( Table 1) .
The ternary matrix (an equimolar mixture of miniGroEL agarose͞DsbA agarose͞PPI agarose) solubilized the greater majority of the sample (87%). Approximately 6% appeared as an HPLC shoulder (peak 2a in Fig. 1C ; Table 1 ) with an elution volume corresponding to Ϸ90 kDa, consistent with dimeric CD1a. An additional shoulder corresponded to possible higherorder oligomers; 15% appeared as a symmetrical peak (2b) with an elution volume corresponding to the expected 44-kDa molecular mass of monomeric CD1a and 60% as a symmetrical chromatographic peak (peak 3) at an elution volume corresponding to 12 kDa (␤ 2 m) ( Table 1 ; Fig. 1B ). At this protein concentration, the peaks were absent if refolding was performed with either minichaperone alone (data not shown), DsbA alone ( Fig. 1 A) , or ethanolamine agarose (Fig. 1 A) . Oxidative refolding of a mixture of denatured͞reduced CD1b heavy chain and ␤ 2 m (ϩL and ϪL) gave peaks corresponding to those seen with CD1a (Fig. 1C) .
It was possible to refold CD1a in the absence of ternary matrix but only in the presence of ligand and if the molarity of the denatured substrates was reduced by three orders of magnitude. The incubation times required for refolding (as indicated by the gain of reactivity to mAb NA1͞34) were in the order of days, as opposed to minutes, when catalyzed by the ternary complex. The yield of refolded material was not, however, increased in the presence of refolding matrix (as compared with ligand only), and it is possible that the ternary matrix uses a similar folding pathway to that induced by the ligand. The ternary matrix enabled the refolding process to be performed with higher molarities of starting products, in smaller reaction volumes, and with much shorter incubation times.
Antigenic and Biochemical Characterization of Refolded CD1a. Soluble samples from refolding protocols (ϩL and ϪL) fractionated by gel-filtration chromatography were collected and tested for activity in an inhibition immunoassay by using the anti-CD1a conformation-sensitive mAb NA1͞34 (Fig. 1B) . Only the unfractionated refolding mixture, fractions 2b (monomeric CD1a Ϸ44 kDa) and 2a (dimeric CD1a Ϸ88 kDa) had activity. This activity was at least as high as that of the positive control (soluble human CD1a secreted by 10B3; Fig. 1B) . The antigenic profile of the refolded CD1a was characterized further by using antiCD1a conformation-sensitive mAbs (19H39.3, B17, and 10D12.2), each of which reacted with both monomeric (Fig. 2C ) and dimeric (data not shown) CD1a. The activity of refolded CD1b was tested by using mAb NU-T2 and ER1 as a target. Only the unfractionated refolding mixture and HPLC-purified CD1b monomer and oligomer had activity (data not shown).
Refolded CD1a and -b supernatants were analyzed by SDS͞PAGE (Fig. 3) , which showed bands of the expected molecular masses. CD1a supernatant was loaded onto an NA1͞34 immuno-affinity column. The high-molecular-mass soluble aggregate and ␤ 2 m did not bind. Bound CD1a was eluted with 0.1 M glycine͞HCl (pH 3.0) into 1.0 M Tris⅐HCl (pH 7.4) and found to react with all four mAbs in the inhibition immunoassay (data not shown). The material was fractionated by SDS͞PAGE and the bands were electroblotted. The identity of the recovered products (bands of molecular mass Ϸ34 and 12 kDa corresponding to the CD1a and -b heavy chain and ␤ 2 m, respectively) was confirmed by NH 2 -terminal amino acid sequence analysis (data not shown). Amino acid analysis of the bands from CD1a and -b was consistent with a 1:1 (heavy͞light chain) stoichiometry (data not shown).
Sedimentation equilibrium runs of the fraction corresponding to peak 3 from the preparative gel filtration (Fig. 2 A) demonstrated that, at protein concentrations of 20 and 70 mM, the refolded ␤ 2 m light chain was monomeric and did not homooligomerize. Analytical ultracentrifugation of fractions corresponding to peak 2a and 2b from the scale-up was performed at concentrations of 20 and 70 M (Fig. 4) . Plots of protein concentration (A 275 nm) against radial position (Fig. 4) were consistent with a mixture of ␤ 2 m light-chain monomers and CD1a complexes that were mostly in a monomeric configuration but in equilibrium with a small quantity of oligomers. After 7 days of ultracentrifugation, the majority of the protein in all samples tested (ϩL and ϪL) remained soluble and active when retested in the inhibition assay (data not shown), indicating that the conformation of the material remained intact. The CD spectra of these samples were indistinguishable from those obtained before the run (data not shown), confirming that the secondary structural elements were intact.
Optimizing Oxidative Refolding Chromatography for CD1. To test whether the folding benefits from ''priming'' with refolded ␤ 2 m, denatured͞reduced CD1a heavy chain was added to a solution containing refolded ␤ 2 m and ternary resin. A dense precipitate formed immediately, and we conclude that it is essential that the CD1 heavy chain and ␤ 2 m light chain are mixed together in the denatured͞reduced state before refolding. The duration of the denaturation step was critically important also. Yields of active refolded protein fell dramatically if denatured inclusion bodies were left at 4°C for more than 24 h (data not shown). It is essential, consequently, to work with freshly denatured material. A range of storage buffers were tested and the refolded molecules found to be stable in an aqueous environment containing 0.06 M GuHCl͞1.0% glycerol. The efficiency of refolding was pH-dependent and favored above neutral values. Under more acidic conditions, the heterodimer dissociated, precipitated, and lost activity (data not shown). A pH of 8.0 was optimal, and all subsequent experiments were performed at this value. Timecourse experiments indicated that refolding efficiency was limited by the time taken to implement the procedure (approximately 6 min) and not by a kinetic barrier. It should be noted, however, that our experiments were configured such that the molar ratios of immobilized chaperones and foldases were in significant (approximately 100-fold) excess relative to their substrates.
When the residual 60 mM GuHCl was removed from the refolding mixture after dilution, the antigenic activity of monomeric and oligomeric CD1a (ϪL) was lost. Low molarity GuHCl seems to help maintain the conformational integrity of the ''empty'' molecules. All results obtained at the analytical level were reproducible at the preparative level (Fig. 2B , data not shown for CD1b). To characterize the stability of the monomeric Yields were calculated as percentage of total protein recovered in the total soluble fraction. *Components of the refolding matrix were coupled independently to NHS-activated Sepharose. † Refers to soluble protein recovered after refolding. ‡ Peak numbers (see Fig. 1 ). Large aggregates after concentration of peak 1 were removed by centrifugation. § 0.12 mg of denatured͞reduced CD1a were added to 4.4 mL of refolding buffer. ¶ 0.12 mg denatured͞reduced CD1a was added to 2 mL of PPI-agarose͞refolding buffer and made up to a final volume of 4.4 mL. 0.12 mg of denatured͞reduced CD1a was added to 3 mL of DsbA-agarose͞refolding buffer and made to a final volume of 4.4 mL. **0.12 mg of denatured͞reduced CD1a was added to 2 mL of minichaperone-agarose͞refolding buffer and made up to a final volume of 4.4 mL. † † 1.2 mg of denatured͞reduced CD1a was added to 1.3 mL of minichaperone-agarose ϩ 2.6 mL DsbA-agarose ϩ 1.1 mL PPI-agarose͞refolding buffer and made up to a final volume of 50 mL.
CD1a complex further, peak 2b was concentrated and loaded onto an analytical HPLC column (Fig. 2C) . Although the majority of the species present corresponded to the 44-kDa molecular mass of the monomeric complex, the peaks were not entirely symmetrical, confirming the ultracentrifugation results and indicating that in addition to free ␤ 2 m, the refolded complex is in dynamic equilibrium with minor species that most likely represent a range of oligomeric CD1a complexes and relatively low-molecular-mass aggregates. The position of the equilibrium depended on protein concentration and could be shifted in a direction favoring production of monomeric CD1a by limiting starting concentrations. Refolding yields under all conditions were reduced significantly if the CD1 and ␤ 2 m were synthesized with a nonnative N terminus (data not shown).
Circular Dichroism Spectroscopy of Refolded CD1a. CD spectra of the refolded CD1a molecules were measured under native and denaturing conditions. Whereas the spectra of the denatured products were consistent with those expected for an unfolded state (data not shown), those from the refolded CD1a monomer (ϩL and ϪL) indicated the presence of secondary structural elements corresponding to ␣-helices and ␤-sheets (Fig. 5) . Spectra obtained from the ϪL and ϩ L conditions were indistinguishable. The presence of glycerol and GuHCl in the refolding buffer (needed to maintain the activity of the empty complex) prevented quantitative analysis of the ␤-sheets.
Discussion
The results demonstrate that the efficient in vitro refolding of a recombinant and fully denatured antigen-presenting molecule is possible in the absence of ligand and suggest that the ligandbinding pathway is not the only route by which stable molecules can be assembled in vivo. When denatured͞reduced MHC class I and ␤ 2 m light chains synthesized in E. coli are refolded in the absence of synthetic ligand, stable complexes are not produced (25, 26) . Furthermore, evidence that the MHC and CD1 molecules expressed in Drosophila melanogaster and other insect expression systems are empty remains elusive. In our case, although we do not suggest that empty implies that the binding site is free of solvent molecules, the procedure used supports the view that the folded material did not harbor ligand or ligand-like components. Indeed, as the heavy and light chains were reduced fully and denatured, it is unlikely that components of the bacterial lysate remained bound to the starting material. The consistent presence of oligomeric forms observed in the chromatographic patterns and deduced from equilibrium centrifugation results raises the question of their functional significance in solution, inside the cell, or on the cell membrane. The misfolding and aggregation of proteins expressed in the cytoplasm of E. coli to form inclusion bodies is a major problem in biotechnology and biomedical research (36) . The Ig supergene family constitutes a significant percentage of the proteins encoded within the human genome (37) . The in vitro synthesis of these functionally diverse proteins is limited by the fact that their expression in prokaryotic systems like E. coli often results in the production of insoluble inclusion bodies that cannot be refolded efficiently or at all. The alternative strategy, which involves expression in eukaryotic hosts, produces significantly lower yields of protein and is considerably more time consuming and expensive. As the CD1 family uses the canonical Ig fold, it may serve as a paradigm for the efficient refolding of other members of this superfamily. Indeed if, as seems likely, all Ig-like ␤-sandwich proteins share a common folding pathway (38) , it is reasonable to suggest that it will be possible to refold other Ig domain-containing proteins by using the method we have described. These proteins include molecules of potential therapeutic, diagnostic, industrial, and biotechnological importance such as CD8, CD4, MHC proteins, and immunoglobulins. The method may, in addition, facilitate the in vitro production of Ig-fold-containing oligomeric complexes, both natural and artificial.
The folding is fast and most likely limited only by the time taken to perform the oxidative refolding chromatography procedure. The ternary resin can be denatured and renatured repeatedly with little or no loss of the immobilized proteins. The method therefore is suitable equally when initial refolding yields are low, because under appropriate conditions, the insoluble starting material could be denatured iteratively and renatured over a short timescale. The method, furthermore, is amenable to scale-up and automation, and if implemented in a bioreactortype device, could allow large-scale production of recombinant multisubunit proteins.
Evidence suggests that calnexin and calreticulin assist the in vivo folding of MHC class I and CD1 molecules (19, 20) . The 4 . Equilibrium sedimentation of refolded CD1a. Experiments were performed at 10,000 rpm, 4°C, by using 50 mM Tris͞60 mM GuHCl͞2% glycerol͞1 mM EDTA. Data are for the CD1a ϪL fraction. Data for the ϩL complex were very similar. Data were fitted to a model-free equation that assumes that the CD1a complex can oligomerize, and that there is an excess of ␤2m. Heavy chain alone was not seen, indicating that the CD1a͞␤2m association is very tight, or͞and that nonassociated heavy chain is insoluble. Logarithms of oligomerization constants (for dimer formation) were estimated to be 4. mechanism by which the GroEL minichaperone assists CD1 folding is most likely different from that of calnexin and calreticulin, both of which recognize glycosylated polypeptides, as compared with GroEL, which interacts with substrate in a sugar-independent manner. Glycosylation may help stabilize the native molecule, but our results suggest that it is not essential for the correct folding of CD1. The fact that it is possible to assemble human CD1 molecules in vitro in the absence of ligand suggests that CD1 and possibly other antigen-presenting molecules may have access to ligand-independent folding pathways. A fraction of the heterodimers expressed in vivo may assemble empty, perhaps associating with ligand derived from exogenous sources or having a function dependent on their ligand-binding capacity. They might, for example, have a role in development, perhaps functioning as T cell selection elements in the cortical thymus. Further investigation will be necessary to establish whether empty CD1 molecules represent a folding intermediate whose ␣-helices are in a partially folded ''molten globule'' state (27, 28) , or whether the CD1 binding site enables ligand-free complexes to fold completely and attain greater stability than their empty MHC class I counterparts. Sequence differences between CD1 isoforms are likely to produce differences in the relative stability of their respective ligand-free forms.
Our results may have therapeutic implications for conditions that affect protein folding and result in the formation of pathogenic intracellular aggregates such as Huntington's disease, Alzheimer's disease, and Parkinson's disease (39) . Indeed, we recently demonstrated that bacterial GroEL fragments reduce aggregate formation and cell death in a mammalian cell model of Huntington's disease (40) . We have shown also that synthetic human CD1d can be refolded with ␣-galactosylceramide ligand by using the oxidative refolding chromatography procedure outlined above. We have used this material to generate tetrameric CD1d molecules that stain T cell clones (41 
